|
SUPV3L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.3336000000439E-06 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.63546953757532E-12 |
| Stage1-vs-Stage2 |
7.521600E-02 |
| Stage1-vs-Stage3 |
3.922800E-01 |
| Stage1-vs-Stage4 |
1.077800E-01 |
| Stage2-vs-Stage3 |
3.303600E-02 |
| Stage2-vs-Stage4 |
1.313570E-02 |
| Stage3-vs-Stage4 |
3.685400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.60879976007777E-10 |
| Normal-vs-Asian |
4.63262761485339E-12 |
| Caucasian-vs-AfricanAmerican |
8.055800E-01 |
| Caucasian-vs-Asian |
3.390400E-01 |
| AfricanAmerican-vs-Asian |
6.576200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.164800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
7.96780419420884E-11 |
| Normal-vs-Age(81-100Yrs) |
4.425800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.202800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.252000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.164200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.204500E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.147200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.197400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.480300E-03 |
| Classical-VS-Follicular |
8.446700E-04 |
| Classical-VS-Other |
3.932200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.39810000002283E-06 |
| Tall-VS-Other |
9.196600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.047160E-01 |
| Follicular-VS-Normal |
4.20759999952836E-07 |
| Other-VS-Normal |
2.63970000002889E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
4.44089209850063E-16 |
| N0-vs-N1 |
7.962700E-03 |
|
|
